Hosted a 2026 outlook webinar discussing portfolio company Syntara.
Syntara
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Syntara
Hashan De Silva - Keys to Successful Life Science Investing
Investing at the inflexion point in healthcare innovation
Punching above our weight: backing world-class Aussie biotechs
The 4 biotech firms the experts are most excited about
CurveBeam AI
Syntara
The 7 biotech stocks (and their trials) these experts are watching right now
Could this be the best market ever for healthcare investing?
Aussie VC investor wants liberalisation of trans-Tasman market
Investor who bought Neuren at $1 a share lowers sights on $200m fund
Be greedy when others are fearful: Why now is the time to invest in healthcare
This fundie invested in Neuren at a $70m valuation. It's now $2.4 billion.
Backed by industry titans, leveraging Australia's healthcare innovation